Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions ; volume:21 ; number:1 ; day:21 ; month:1 ; year:2022 ; pages:1-27 ; date:12.2022
Molecular cancer ; 21, Heft 1 (21.1.2022), 1-27, 12.2022
- Urheber
-
Yi, Ming
Zheng, Xiaoli
Niu, Mengke
Zhu, Shuangli
Ge, Hong
Wu, Kongming
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-021-01489-2
- URN
-
urn:nbn:de:101:1-2022050219473580368898
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yi, Ming
- Zheng, Xiaoli
- Niu, Mengke
- Zhu, Shuangli
- Ge, Hong
- Wu, Kongming
- SpringerLink (Online service)
Ähnliche Objekte (12)
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Regulatory mechanisms of PD-1/PD-L1 in cancers
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Regulatory mechanisms of PD-1/PD-L1 in cancers
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer